Graded A to F on human evidence · reviewed November 20, 2026
Best Peptide for Longevity (2026)
Peptides sold for longevity, graded on the human evidence for markers of aging. No peptide has been shown to make people live longer, so these grades cover what studies in older adults measured.
By Julian Caraulani · prices checked
For healthy aging, Sermorelin has the strongest human evidence of the peptides US programs sell: grade B (some human evidence). NAD+ grades C, Epitalon grades C, MOTS-c grades D. None is FDA-approved for longevity when compounded. Grades follow our published rubric; prices come from each program's own page, with the date we read it.
Price checked Nov 19 · Medication included · No email needed
Longevity peptides, graded
Strongest evidence first. The grade covers healthy aging only; the same peptide can grade differently for another goal.
| Grade | Peptide | FDA status | Lowest price |
|---|---|---|---|
| B | Sermorelin Some human evidence Former brand GEREF. FDA found it was not withdrawn from sale for safety or effectiveness reasons. Not on the 14 May 2026 category list, and no source here states its compounding status today. | Former brand GEREF. FDA found it was not withdrawn from sale for safety or effectiveness reasons. Not on the 14 May 2026 category list, and no source here states its compounding status today. | $94/mo Idun Rx, 17 programs |
| C | NAD+ Early human evidence FDA Category 1. Not FDA-approved when compounded. | FDA Category 1. Not FDA-approved when compounded. | $89/mo bmiMD, 14 programs |
| C | Epitalon Early human evidence Interim HHS enforcement discretion, acetate form, injection routes, intermittent courses. Not FDA-approved. | Interim HHS enforcement discretion, acetate form, injection routes, intermittent courses. Not FDA-approved. | $199/mo HealthRX, 1 program |
| D | MOTS-c Preclinical only Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved. | Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved. | $129/mo HealthRX, 3 programs |
Sermorelin for longevity: grade B
Some human evidence
What the human evidence shows. A placebo-controlled trial in adults aged 55 to 71 found higher IGF-1, thicker skin in both sexes and more lean mass in men. It did not measure lifespan.
Sources: Khorram 1997, J Clin Endocrinol Metab. Read November 20, 2026.
Regulatory status: Former brand GEREF. FDA found it was not withdrawn from sale for safety or effectiveness reasons. Not on the 14 May 2026 category list, and no source here states its compounding status today.
“were not withdrawn from sale for reasons of safety or effectiveness” Federal Register, 4 Mar 2013: GEREF (sermorelin acetate) determination, read November 6, 2026
Sermorelin programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
Sermorelin, 12 months | Sermorelin, 12 months | $94/moread November 19, 2026 | 8.7/10 | Visit |
Sermorelin injection | Sermorelin injection | $99/moread November 19, 2026 | 8.7/10 | Visit |
Sermorelin injection, from price | Sermorelin injection, from price | $99/moread November 19, 2026 | 8.3/10 | Visit |
Sermorelin, starting price | Sermorelin, starting price | $99/moread November 19, 2026 | 7.6/10 | Visit |
Sermorelin lozenge, 30-day supply | Sermorelin lozenge, 30-day supply | $99/moread November 19, 2026 | 7.4/10 | Visit |
12 more on cheapest sermorelin · Sermorelin cost
NAD+ for longevity: grade C
Early human evidence
What the human evidence shows. A small pilot study of an NAD+ drip measured how blood and urine levels changed over six hours. It did not measure health outcomes. Pills that the body turns into NAD+ have more trials, but programs here sell NAD+ itself.
Sources: Grant 2019, Front Aging Neurosci. Read November 20, 2026.
Regulatory status: FDA Category 1. Not FDA-approved when compounded.
“Nicotinamide Adenine Dinucleotide (NAD)” FDA: Bulk drug substances nominated under section 503A (category list), read November 18, 2026
NAD+ programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
NAD+ injection, 12 months | NAD+ injection, 12 months | $89/moread November 15, 2026 | 8.4/10 | Visit |
Compounded NAD+ injections or nasal spray | Compounded NAD+ injections or nasal spray | $99/moread November 19, 2026 | 8.7/10 | Visit |
NAD+ injection, from price | NAD+ injection, from price | $99/moread November 19, 2026 | 8.3/10 | Visit |
NAD+ nasal spray, 12-month plan | NAD+ nasal spray, 12-month plan | $107/moread November 19, 2026 | 8.3/10 | Visit |
NAD+ injection, 12 months | NAD+ injection, 12 months | $109/moread November 19, 2026 | 8.7/10 | Visit |
9 more on cheapest NAD+ · NAD+ cost
Epitalon for longevity: grade C
Early human evidence
What the human evidence shows. Human studies come from one Russian research group, mostly on melatonin rhythm in older people. No study outside Russia has tested it in people, and FDA's review found no clinical data on its safety.
Sources: Korkushko 2004, Bull Exp Biol Med. Read November 20, 2026.
Regulatory status: Interim HHS enforcement discretion, acetate form, injection routes, intermittent courses. Not FDA-approved.
“epitalon acetate is appropriate subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses” HHS Enforcement Discretion Policy with Appendices A and B, read November 18, 2026
Epitalon programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
Epitalon injection, 1-month plan | Epitalon injection, 1-month plan | $199/moread November 19, 2026 | 8.3/10 | Visit |
Every plan on cheapest epitalon · Epitalon cost
MOTS-c for longevity: grade D
Preclinical only
What the human evidence shows. We found no published trial that gave MOTS-c to people. The human studies measured the body's own levels.
Sources: FDA: bulk drug substances that may present significant safety risks. Read November 20, 2026.
Regulatory status: Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved.
“enforcement discretion for MOTS-c acetate is appropriate subcutaneous or intramuscular injectable dosage forms” HHS Enforcement Discretion Policy with Appendices A and B, read November 18, 2026
MOTS-c programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
MOTS-c injection, 12-month plan | MOTS-c injection, 12-month plan | $129/moread November 19, 2026 | 8.3/10 | Visit |
MOTS-c injection (preorder) | MOTS-c injection (preorder) | $199/moread November 19, 2026 | 8.0/10 | Visit |
MOTS-c injection | MOTS-c injection | $274.50/moread November 20, 2026 | 8.3/10 | Visit |
Every plan on cheapest MOTS-c · MOTS-c cost
How these grades are set
One fixed rubric for every goal: A means FDA-approved for the goal, or at least two randomized trials in people that found a benefit. B means at least one human trial, or approval outside the US backed by trials. C means pilot or foreign-only human data. D means preclinical studies only. F means human trials found no benefit. When trials disagree, the grade drops one step. Read the full rubric.
We do not publish doses, schedules or combinations. A licensed prescriber decides whether any peptide suits you. Compounded peptides are not FDA-approved products.
Questions about peptides for longevity
What is the best peptide for longevity?
No peptide has been shown to extend life in people. On markers of aging, sermorelin grades highest (B, one placebo-controlled trial in older adults). NAD+ and epitalon grade C, and MOTS-c grades D.
Is NAD+ proven to slow aging?
No. The human study of NAD+ itself that we graded was a small pilot measuring blood levels, not aging. It grades C.
How do you grade peptides for longevity?
With one fixed A to F rubric for every goal: A means FDA-approved for the goal or at least two randomized trials in people that found a benefit; B at least one human trial or approval outside the US backed by trials; C pilot or foreign-only human data; D preclinical only; F human trials found no benefit. The full rules are on our methodology page.
Do you say how much to take?
No. We publish evidence grades, regulatory status and prices only. We do not publish doses, schedules or combinations. A licensed prescriber decides whether any of these suits you and how it is used.